The clinical significance of CD34 expression in response to therapy of patients with acute myeloid leukemia : An overview of 2483 patients from 22 studies
✍ Scribed by Yoshinobu Kanda; Tamae Hamaki; Rie Yamamoto; Aki Chizuka; Miyuki Suguro; Tomohiro Matsuyama; Naoki Takezako; Akiyoshi Miwa; Masahiro Kami; Hisamaru Hirai; Atsushi Togawa
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- English
- Weight
- 119 KB
- Volume
- 88
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
BACKGROUND.
Although many studies have been performed to evaluate the prognostic significance of CD34 expression in acute myeloid leukemia (AML), the findings have been inconsistent. In this study, the authors reviewed such previous studies to establish a definite conclusion.
METHODS.
Using MEDLINE, the authors identified studies that evaluated the prognostic significance of CD34 expression in AML. The outcome measure was the complete remission rate. They used the random-effect method to combine the results. Results were presented as odds ratios (ORs) with 95% confidence intervals (CIs). The ORs were less than 1 if the complete remission occurred more frequently in the CD34 negative group.
RESULTS.
Twenty-two studies including 2483 patients were reviewed. The combined OR was 0.38 (95% CI, 0.26 -0.57), which suggested that CD34 expression was associated with a poor remission rate. However, the authors found statistical evidence of marked heterogeneity among trials (P Ͻ 0.001), especially according to time of publication. The combined OR in studies published in or after 1994 was 0.70 (95% CI, 0.47-1.09). The authors divided the studies into several subgroups, but they could not determine the reason for the heterogeneity.
CONCLUSIONS.
At present, CD34 expression should not be considered a marker of poor prognosis because it is not supported by the combined data from recent studies. Further studies should be conducted to investigate the intensity of CD34 expression in specific populations of patients, such as those with t(8;21) or t(15;17) translocations or the AML-M0 subtype.